S 2074 — Mainstreaming Addiction Treatment Act of 2019

Summary

Mainstreaming Addiction Treatment Act of 2019 This bill removes the requirement that a health care practitioner apply for a separate waiver through the Drug Enforcement Administration (DEA) to dispense certain narcotic drugs (e.g., buprenorphine) for maintenance or detoxification treatment (i.e., substance use disorder treatment). Further, a community health aide or community health practitioner may dispense certain narcotic drugs for maintenance or detoxification treatment without registering with the DEA if the drug is prescribed by a health care practitioner through telemedicine. It preempts state laws related to licensure for this activity. The bill also directs the Substance Abuse and Mental Health Services Administration to conduct a national campaign to educate health care practitioners and encourage them to integrate substance use disorder treatment into their practices.

Bill Text

• Introduced Introduced in Senate Current html July 10, 2019

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill eliminates the separate registration requirement for dispensing certain narcotic drugs for maintenance or detoxification treatment.

• 21 U.S.C. 823(g)

  (2)

  The bill removes the separate registration requirement for practitioners dispensing narcotic drugs in schedules III, IV, or V for maintenance or detoxification treatment.

• 21 U.S.C. 823(g)

  (g)(1) Except as provided in paragraph (2), practitioners who dispense narcotic drugs to individuals for maintenance treatment or detoxification treatment → (g) Practitioners who dispense narcotic drugs (other than narcotic drugs in schedule III, IV, or V) to individuals for maintenance treatment or detoxification treatment

  The bill modifies the provision to clarify that it does not apply to narcotic drugs in schedules III, IV, or V.

• 21 U.S.C. 824

  303(g)(1) → 303(g)

  The bill updates references in the registration provisions to reflect changes made to section 303(g).

• 21 U.S.C. 824

  303(g)(1) → 303(g)

  The bill ensures consistency in referring to section 303(g) for suspension and revocation requirements.

• 21 U.S.C. 829a(a)

  (2) → (2) the controlled substance--

  The bill updates the provisions for controlled substances to include modifications related to their administration.

• 21 U.S.C. 829a(a)

  is a drug in schedule III, IV, or V to be administered-- → is a narcotic drug in schedule III, IV, or V to be administered for the purpose of maintenance or detoxification treatment; and

  The bill specifies that the drug must be a narcotic for maintenance or detoxification purposes.

• 42 U.S.C. 290bb-36d(c)

  information on any qualified practitioner that is certified to prescribe medication for opioid dependency under section 303(g)(2)(B) of the Controlled Substances Act → information on any practitioner who prescribes narcotic drugs in schedule III, IV, or V of section 202 of the Controlled Substances Act for the purpose of maintenance or detoxification treatment

  The bill updates references to practitioners who prescribe narcotic drugs for specific treatments.

• 42 U.S.C. 290dd-3

  any practitioner dispensing narcotic drugs pursuant to section 303(g) of the Controlled Substances Act → any practitioner dispensing narcotic drugs for the purpose of maintenance or detoxification treatment

  The bill simplifies the language describing practitioners dispensing narcotic drugs.

• 42 U.S.C. 1395l(bb)(3)(B)

  first receives a waiver under section 303(g) of the Controlled Substances Act on or after January 1, 2019 → first begins prescribing narcotic drugs in schedule III, IV, or V of section 202 of the Controlled Substances Act for the purpose of maintenance or detoxification treatment on or after January 1, 2019

  The bill updates the reference for practitioners regarding their prescribing capabilities after a specific date.

• 42 U.S.C. 1395m(o)(3)(C)(ii)

  first receives a waiver under section 303(g) of the Controlled Substances Act on or after January 1, 2019 → first begins prescribing narcotic drugs in schedule III, IV, or V of section 202 of the Controlled Substances Act for the purpose of maintenance or detoxification treatment on or after January 1, 2019

  The bill clarifies the conditions under which practitioners may begin prescribing regulated drugs.

• 42 U.S.C. 1395cc-6(c)(3)

  ; and

  The bill removes an unnecessary clause in the legislation.

• 42 U.S.C. 1396b(aa)(2)(C)

  (ii)

  The bill removes an unnecessary clause in the legislation.

• 42 U.S.C. 1396b(aa)(2)(C)

  clause (ii) → clause (ii)

  The bill redesignates remaining clauses for consistency.

Action History

1. July 10, 2019

   Introduced in Senate

2. July 10, 2019

   Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

• Lisa Murkowski · Cosponsor
• Dan Sullivan · Cosponsor
• Michael F. Bennet · Cosponsor
• Jeff Merkley · Cosponsor
• Cindy Hyde-Smith · Cosponsor
• Margaret Wood Hassan · Primary

Subjects